Glenmark Pharmaceuticals Inc., USA, a subsidiary of Glenmark Pharmaceuticals Ltd., has announced the upcoming launch of Micafungin for Injection USP, 50 mg/vial and 100 mg/vial (Single-Dose Vial). The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine® for Injection by Astellas Pharma US, Inc. (NDA – 021506). The company confirmed that distribution will begin in September 2025.
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine® for Injection market (50 mg/vial and 100 mg/vial) generated approximately $60.7 million in annual sales. Glenmark aims to capture a share of this market by offering a high-quality and more affordable alternative.
Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “We are excited to introduce Micafungin for Injection USP, further strengthening our institutional product portfolio and reinforcing our commitment to deliver accessible, affordable, and quality medicines to patients in need.”
The new launch is expected to expand Glenmark’s presence in the U.S. injectable market while enhancing treatment options for patients.
